Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05153525

Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Clinical Trial

Official title:
Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome

Clinical Trial Summary

The aim of this work is to compare continuous infusion vs on need intermittent boluses of Cisatracurium in the early management of pediatric acute respiratory distress syndrome

Clinical Trial Description

In the pediatric population, Acute respiratory distress syndrome (ARDS) has a high mortality rate of approximately 24%. In addition, there is a lack of high-quality data to guide the use of non-depolarizing neuromuscular blocking agents (NMBAs) in mechanically ventilated children. Hence, there is a need to evaluate its use in pediatrics. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05153525
Study type Interventional
Source Tanta University
Contact Mohamed Khaled Talaat, PharmD
Phone 00201067967640
Email mohamedktalaat@pharm.tanta.edu.eg
Status Recruiting
Phase Phase 4
Start date January 6, 2022
Completion date August 5, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05807802 - FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis
Recruiting NCT05002478 - Infants With Severe Acute Respiratory Distress Syndrome: The Prone Trial N/A
Completed NCT04389671 - The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) Phase 2
Not yet recruiting NCT06147674 - Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
Completed NCT04607434 - Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury
Completed NCT04381338 - Rehabilitation for People With COVID-19 in ICU N/A
Terminated NCT04360096 - Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 Phase 2/Phase 3
Not yet recruiting NCT06123962 - ALI/ARDS Clinical Sub-phenotyping Study
Withdrawn NCT05137795 - Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 Phase 3
Recruiting NCT04935697 - Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress N/A
Withdrawn NCT04482712 - Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS Phase 1/Phase 2
Not yet recruiting NCT05343338 - Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium N/A
No longer available NCT04355494 - SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19